ArticleDiscover oncology2025
Integrative Mendelian randomization and spatial transcriptomics analysis reveals causal links between plasma lipidome and non-small cell lung cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study aimed to investigate the potential causal relationship between plasma lipidome and non-small cell lung cancer (NSCLC) using a two-sample Mendelian randomization (MR) approach based on large-scale genome-wide association study (GWAS) data.
methodsA two-sample bidirectional MR analysis was conducted using summary-level data from the GeneRISK and FinnGen GWAS. Genetic instruments were selected for 179 plasma lipid traits. Causal effects were estimated using inverse variance weighting (IVW), MR-Egger, weighted median, and Mendelian Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO) methods. Spatial transcriptomic profiling and machine learning-based gene prioritization were further employed to explore potential mechanistic links.
resultsMR identified 30 lipid species significantly associated with NSCLC risk, of which 17 demonstrated consistent causal effects across multiple sensitivity analyses. A subset of phosphatidylcholine and phosphatidylethanolamine species exhibited inverse associations, indicating potential protective effects, while specific sterol esters, sphingomyelins, and triacylglycerols were positively associated with disease susceptibility. Plasmacytoma Variant Translocation 1 (PVT1) was first prioritized as a key lipid-associated gene by three machine learning algorithms and was subsequently validated by spatial transcriptomics, showing elevated expression in tumor-dense regions.
conclusionThis study reveals a causal link between distinct plasma lipid species and NSCLC risk, emphasizing the role of lipid structural diversity. PVT1 may act as a critical mediator connecting lipid dysregulation to lung tumorigenesis, offering novel biomarker and therapeutic target potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.